Evommune, Inc.
EVMN$892M
Small CapNASDAQBiotechnology🇺🇸North America45 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jul 15, 2026
8wMarket Overview
Stock performance and key metrics
EVMN News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
EVO101
Atopic Dermatitis Eczema
Oral EVO756
Chronic Inducible Urticaria
EVO756
Chronic Spontaneous Urticaria
EVO301
Atopic Dermatitis (AD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EVO101 | Phase 2 | Atopic Dermatitis Eczema | - | - |
Oral EVO756 | Phase 2 | Chronic Inducible Urticaria | - | - |
EVO756 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
EVO301 | Phase 2 | Atopic Dermatitis (AD) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply